Patents by Inventor Martina Zimmermann

Martina Zimmermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for modulating the glycosylation profile of proteins
    Publication number: 20230022796
    Abstract: The present invention relates to cell culture media comprising 5-Thio-L-fucose and the use of 5-Thio-L-fucose for modulating the glycosylation profile of antibodies or other Fc containing proteins and thereby modulating the binding affinity of said proteins.
    Type: Application
    Filed: December 16, 2020
    Publication date: January 26, 2023
    Applicant: Merck Patent GmbH
    Inventors: Aline ZIMMER, Janike EHRET, Martina ZIMMERMANN
  • Genetically modified paramyxovirus for treatment of tumor diseases
    Patent number: 9821016
    Abstract: The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 21, 2017
    Assignee: Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
    Inventors: Ulrich Manfred Lauer, Michael Bitzer, Martina Zimmermann, Sorin Armeanu-Ebinger, Sascha Bossow, Wolfgang Neubert
  • Oncolytic measles virus
    Patent number: 9272008
    Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 1, 2016
    Inventors: Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Zimmermann, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow
  • Oncolytic Measles Virus
    Publication number: 20150250838
    Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
    Type: Application
    Filed: May 22, 2015
    Publication date: September 10, 2015
    Inventors: Ulrich M. LAUER, Michael BITZER, Johanna LAMPE, Martina ZIMMERMANN, Susanne BERCHTOLD, Sebastian LANGE, Wolfgang J. NEUBERT, Sascha BOSSOW
  • Oncolytic Measles Virus
    Publication number: 20130217757
    Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
    Type: Application
    Filed: August 19, 2011
    Publication date: August 22, 2013
    Inventors: Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Zimmermann, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow